[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wollina et al., 2001 - Google Patents

Serum matrix metalloproteinase-2 in patients with malignant melanoma

Wollina et al., 2001

Document ID
14178791147877013020
Author
Wollina U
Hipler U
Knöll B
Graefe T
Kaatz M
Kirsch K
Publication year
Publication venue
Journal of cancer research and clinical oncology

External Links

Snippet

Purpose: Matrix metalloproteinases (MMPs) are a family of structurally related zinc- dependent endopeptidases that are able to degrade extracellular matrix components. MMPs play a role in tumor invasion and tumor metastasis. MMP-2 (also known as gelatinase A) is …
Continue reading at link.springer.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/573Immunoassay; Biospecific binding assay for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Nikkola et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma
Catalona et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
Platts et al. Death from phaeochromocytoma: lessons from a post-mortem survey
RU2580626C2 (en) Use of vap-1 inhibitors for fibrotic sickness treatment
Väisänen et al. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma
Wang et al. Post-treatment surveillance of thyroid cancer
Schlagenhauff et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
CA2330628A1 (en) Method for diagnosing a vascular condition
JP2013083665A (en) Use of melanoma inhibitory activity (mia) protein as early indicator for therapeutic response in melanoma
Larrinaga et al. Prolyl endopeptidase activity is correlated with colorectal cancer prognosis
Protheroe et al. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer
Glimelius et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements
Wollina et al. Serum matrix metalloproteinase-2 in patients with malignant melanoma
Karvonen et al. An animal model of pulmonary radiation fibrosis with biochemical, physiologic, immunologic, and morphologic observations
Khongkhunthian et al. Elevated levels of a disintegrin and metalloproteinase 8 in gingival crevicular fluid of patients with periodontal diseases
Jassem et al. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance
RU2219553C2 (en) Method for determining autohemochemotherapy effectiveness in treating the cases of carcinoma affecting rectosigmoid portion of the rectum and sigmoid colon and autohemochemotherapy combined with ultrahigh frequency hyperthermia in treating the cases of rectal carcinoma
Sciarra et al. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma
Faraj et al. Plasma L-dopa in the diagnosis of malignant melanoma.
RU2635535C1 (en) Method for prediction of relapse development in patients with oral mucosa cancer
US6352834B1 (en) Prostate cancer assays and related methods
EP1181939B1 (en) Method for evaluating in vivo matrix metalloproteinase inhibitory activity
RU2548783C1 (en) Method for preoperative determination of extent of surgery for high-differentiated thyroid carcinoma
RU2605838C1 (en) Method for prediction of risk of biochemical recurrent in prostate cancer patients after radiation and hormone therapy
Moseley et al. Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors